scholarly journals Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants

2021 ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background: This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients. Methods: One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups. Results: The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p=0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2±10.0 vs 23.6±16.1 d; p<0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable. Conclusions: Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants and reduce the exposure time of antibiotics, without causing obvious side complications.

scholarly journals Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants

2020 ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background: This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients.Methods: One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups.Results: The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p=0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2±10.0 vs 23.6±16.1 d; p<0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable.Conclusions: Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants, prolong the usage time of PICC line, and reduce the exposure time of antibiotics, without causing obvious side complications.

scholarly journals Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants

2020 ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background: This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients. Methods: One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups. Results: The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p =0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2±10.0 vs 23.6±16.1 d; p <0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable. Conclusions: Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants and reduce the exposure time of antibiotics, without causing obvious side complications.

scholarly journals Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients. Methods One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups. Results The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p = 0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2 ± 10.0 vs 23.6 ± 16.1 d; p < 0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable. Conclusions Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants and reduce the exposure time of antibiotics, without causing obvious side complications.

scholarly journals Vancomycin-Lock Therapy for Prevention of Catheter-Related Bloodstream Infection in Very Low Body Weight Infants

2020 ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background: This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients.Methods: One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups.Results: The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p=0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2±10.0 vs 23.6±16.1 d; p<0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable.Conclusions: Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants, prolong the usage time of PICC line, and reduce the exposure time of antibiotics, without causing obvious side complications.

scholarly journals Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants 

2020 ◽  
Author(s):  
Hong Liang ◽  
Lian Zhang ◽  
Xiaoping Guo ◽  
Li Sun
Keyword(s):  
Body Weight ◽  
Bloodstream Infection ◽  
Preterm Infants ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Antibiotic Exposure ◽  
Blood Concentrations ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

Abstract Background: This study was to evaluate the effectiveness and safety of vancomycin- lock therapy for the prevention of catheter-related bloodstream infection (CRBSI) in very low body weight (VLBW) preterm infant patients.Methods: One hundred and thirty-seven cases of VLBW preterm infants who retained peripherally inserted central catheters (PICCs) were retrospectively reviewed, including 68 treating with heparin plus vancomycin (vancomycin-lock group) and 69 with heparin only (control group). The incidence of CRBSI, related pathogenic bacteria, adverse events during the treatment, complications, antibiotic exposure, PICC usage time, hospital stay, etc. were compared between the above two groups.Results: The incidence rate of CRBSI in the vancomycin-lock group (4.4%, 3/68) was significantly less than in the control group (21.7%, 15/69, p=0.004). Total antibiotic exposure time during the whole observation period was significantly shorter in the group than in the control group (11.2±10.0 vs 23.6±16.1 d; p<0.001). No hypoglycemia occurred during the locking, and the blood concentrations of vancomycin were not detectable.Conclusions: Vancomycin-lock may effectively prevent CRBSI in Chinese VLBW preterm infants and reduce the exposure time of antibiotics, without causing obvious side complications.

Successful tigecycline lock therapy in a Lactobacillus rhamnosus catheter-related bloodstream infection

Infection ◽  
2011 ◽  
Vol 40 (3) ◽  
pp. 331-334 ◽  
Author(s):  
F. Bartalesi ◽  
S. Veloci ◽  
F. Baragli ◽  
E. Mantengoli ◽  
S. Guidi ◽  
...  
Keyword(s):  
Bloodstream Infection ◽  
Lactobacillus Rhamnosus ◽  
Lock Therapy ◽  
Catheter Related Bloodstream Infection

scholarly journals Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Mark C. Heit ◽  
L. Jay Stallons ◽  
Wolfgang Seewald ◽  
Caryn M Thompson ◽  
Céline E. Toutain ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Consumption ◽  
Day Treatment ◽  
Oral Treatment ◽  
Subcutaneous Administration ◽  
Systemic Exposure ◽  
Control Group ◽  
Serious Adverse Events ◽  
Blood Concentrations ◽  
Daily Dose

Abstract Background Robenacoxib (Onsior™) is a non-steroidal anti-inflammatory drug developed for canine and feline use for the control of pain and inflammation. It is available as both tablets and solution for injection. The objective of this study was to evaluate the safety of the interchangeable use of commercially available robenacoxib formulations when administered to cats orally using 6 mg tablets and subcutaneously using a solution for injection containing 20 mg/mL. Thirty-four naïve healthy 4-month old cats were enrolled in this 37-day study and were randomized to four groups (three robenacoxib and one control). One robenacoxib group received the maximum recommended dose (MRD) rate of each formulation, while the other two received two and three times this dose rate. The cats underwent three 10-day treatment cycles comprised of seven days of once daily oral administration followed by three days of subcutaneous administration. The third cycle was followed by an additional seven days of oral treatment. The control group received oral empty gelatin capsules or subcutaneous saline injections. Assessment of safety was based on general health observations, clinical observations, physical, ophthalmic, electrocardiographic and neurological examinations, clinical pathology evaluations, food consumption, body weight, and macroscopic and microscopic examinations. Blood samples were collected for toxicokinetic evaluation. Results Blood concentrations of robenacoxib confirmed systemic exposure of all treated cats. All cats were in good health through study termination and there were no serious adverse events during the study. There were no changes in body weight, food consumption, ophthalmic, physical or neurological examinations during the study. Treatment-related abnormalities were of low occurrence at all doses and included injection site changes (transient edema with minimal or mild, subacute/chronic inflammation histologically) and prolongation of the QT interval. These findings were consistent with previously observed findings in studies with robenacoxib administered separately orally or subcutaneously in cats. Thus, there were no adverse effects that could be attributed specifically to the interchangeable use of oral and injectable robenacoxib. Conclusions This 37-day laboratory study supports the safety of interchanging robenacoxib injection at a daily dose of 2 mg/kg with robenacoxib tablets at a daily dose of 1 mg/kg, or vice versa.

scholarly journals Differences in photodynamic therapy exposure time and Staphylococcus aureus counts

2018 ◽  
Vol 51 (2) ◽  
pp. 95
Author(s):  
Adeline Jovita Tambayong ◽  
Ira Widjiastuti ◽  
Cecilia G. J. Lunardhi
Keyword(s):  
Staphylococcus Aureus ◽  
Photodynamic Therapy ◽  
Exposure Time ◽  
Pathogenic Bacteria ◽  
Control Group ◽  
Treatment Groups ◽  
Root Canals ◽  
And Staphylococcus Aureus ◽  
Number Of Bacteria ◽  
Colony Counter

Background: The success of endodontic treatment can be achieved when pathogenic bacteria are eliminated from the root canal and periapical tissue resulting in healing of such tissue. One of the bacteria located in root canals is Staphylococcus aureus (S. aureus) reportedly found to be in severe periapical abscesses. Photodynamic therapy is one current technology that can help eliminate microorganisms without causing damage to human body cells. Average of research has been conducted using different tools and bacteria to evaluate the effects of exposure time used in photodynamic therapy on the number of bacteria. Purpose: The research reported here aimed to determine the correlation between the exposure time of photodynamic therapy and the number of S. aureus bacteria. Methods: The S. aureus bacteria used in this research were divided into seven treatment groups: a control group and six treatment groups with respective exposure times of 10, 20, 30, 40, 50 and 60 seconds. All of the bacteria were administered a photosensitiser and radiated according to the treatment intended for each group. They were then planted in nutrient agar and incubated for 48 hours. The colonies of bacteria formed were calculated using the Quebec colony counter and subsequently analyzed by means of both Kruskal Wallis and Mann Whitney U tests. Results: After calculating the number of bacterial colonies, the average number of Staphylococcus aureus bacteria in the non-irradiated group was 119 CFU/ml, 29 CFU/ml in the group with a 10-second exposure time, 20 CFU/ml in the group with a 20-second exposure time, 13 CFU/ml in the group with a 30-second exposure time, 7 CFU/ml in the group with a 40-second exposure time, but none in the groups with exposure times of 50 or 60 seconds. Conclusion: The longer the photodynamic therapy exposure time, the greater the number of S. aureus bacteria eliminated. An exposure time of 50 seconds was found to be sufficient to exterminate all S. aureus bacteria present.

Sign in / Sign up

Export Citation Format

Share Document